Entecavir prophylaxis + Therapeutic entecavir

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Non Hodgkin's Lymphoma

Conditions

Non Hodgkin's Lymphoma, Hepatitis B

Trial Timeline

Apr 1, 2009 → Nov 1, 2012

NCT ID

NCT00926757

About Entecavir prophylaxis + Therapeutic entecavir

Entecavir prophylaxis + Therapeutic entecavir is a approved stage product being developed by Bristol Myers Squibb for Non Hodgkin's Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00926757. Target conditions include Non Hodgkin's Lymphoma, Hepatitis B.

What happened to similar drugs?

4 of 20 similar drugs in Non Hodgkin's Lymphoma were approved

Approved (4) Terminated (4) Active (12)

❌Nivolumab + Brentuximab vedotinOno PharmaceuticalPhase 3

🔄R-mabHDI and ABVD + ABVDEli LillyPhase 3

🔄Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3

🔄Zoledronic Acid + Vitamin D + Calcium CarbonateNovartisPhase 3

❌Ofatumumab + Rituximab + Ofatumumab + RituximabNovartisPhase 3

🔄Panobinostat + PlaceboNovartisPhase 3

🔄rituximab [MabThera/Rituxan] + Standard chemotherapyRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00926757	Approved	Completed	Apr 1, 2009	Nov 1, 2012	Non Hodgkin's Lymphoma

Competing Products

20 competing products in Non Hodgkin's Lymphoma

See all competitors

Product	Company	Stage	Hype Score
YM155 + Rituximab	Astellas Pharma	Phase 2	35
Tazemetostat	Eisai	Phase 2	35
ONTAK	Eisai	Phase 2	35
Tazemetostat	Eisai	Phase 1	29
ME-401	Kyowa Kirin	Phase 1	29
ME-401	Kyowa Kirin	Phase 2	39
Nivolumab + Brentuximab vedotin	Ono Pharmaceutical	Phase 3	32
R-mabHDI and ABVD + ABVD	Eli Lilly	Phase 3	36
Prednisone + Vinblastine + Doxorubicin (Adriamycin) + Gemcitabine	Eli Lilly	Phase 1/2	32
gemcitabine	Eli Lilly	Phase 2	27
gemcitabine + cisplatin + dexamethasone	Eli Lilly	Phase 2	35
R-mabHD + ABVD	Eli Lilly	Phase 2	31
LY317615	Eli Lilly	Phase 2	35
LY4584180 + Rituximab	Eli Lilly	Phase 1	36
Bortezomib + Rituximab + Rituximab	Johnson & Johnson	Phase 3	40
HRS-3738	Jiangsu Hengrui Medicine	Phase 1	25
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-Oxaliplatin	Jiangsu Hengrui Medicine	Phase 2	31
ABT-199 + Ketoconazole	AbbVie	Phase 1	29
ABT-199 + Rifampin	AbbVie	Phase 1	21
[14C]ABT-199 (GDC-0199)	AbbVie	Phase 1	21